Oculis Holding AG announced that the European Medicines Agency (EMA) has granted PRIME designation to its neuroprotective drug candidate Privosegtor for treating optic neuritis, a serious eye condition often linked to multiple sclerosis. This follows a recent Breakthrough Therapy designation from the U.S. FDA, highlighting strong regulatory support. Privosegtor showed promising Phase 2 trial results, improving vision and providing neuroprotection, addressing a significant unmet medical need with no current treatments available. Oculis is now advancing global registrational trials under its PIONEER program to potentially bring this first-in-class therapy to patients faster.
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
